Mate, just an opinion. I think mesenchymal stem cells is very competitive busy field with a host of companies pursuing potential uses, whereas OCC has literally cornered the regenerative market on tendons with its definitively different tenocyte approach and patents therein. That and the widespread potential and superior performance of CelGro in the scaffolding field, I see higher eventual potential revenues.
i am invested in both and think both have tremendous revenue potential, just less potential competitive encroachment on OCC's revenues. Just an opinion and like you know what...we all have those.
Ann: Orthocell receives A$2.9m R&D tax incentive refund, page-54
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
0.010(2.60%) |
Mkt cap ! $82.68M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 39.5¢ | 38.5¢ | $28.61K | 74.11K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 5000 | 1 |
View Market Depth
| Last trade - 15.57pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
39.5¢ |
Change
0.010 ( 2.60 %) |
||||
| Open | High | Low | Volume | ||
| 39.5¢ | 39.5¢ | 39.5¢ | 2000 | ||
| Last updated 14.09pm 03/05/2024 ? | |||||
| OCC (ASX) Chart |